fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Four year data for Wegovy (semaglutide) in obesity presented at ECO meeting and published in Nature – Novo Nordisk

Written by | 18 May 2024

At the European Congress on Obesity in Venice, investigators unveiled results from an analysis published in Nature Medicine evaluating Wegovy’s weight loss benefits over four years. With this… read more.

One in five state Medicaid programs covers weight loss medications

Written by | 18 Mar 2024

Mounting evidence suggests that FDA-approved weight loss medications, such as Wegovy, not only help patients lose weight but also protect against complications from obesity such as cardiovascular disease…. read more.

Wegovy approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease – Novo Nordisk

Written by | 14 Mar 2024

Novo Nordisk announced that the FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of… read more.

Alarm over lax oversight of weight loss drug ads that could harm patients

Written by | 19 Dec 2023

UK organisations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law,… read more.

Mounjaro versus Wegovy in treatment of Obesity – Eli Lilly

Written by | 9 Dec 2023

Overweight or obese adults lost more weight and shed pounds faster using Mounjaro than those taking Novo Nordisk’s rival weight loss drug (Wegovy/Ozempic)) according to an analysis of… read more.

Semaglutide (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss

Written by | 5 Oct 2023

Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up… read more.

Pharmacy-led obesity management with GLP agonists

Written by | 21 Jun 2023

Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short… read more.

Offering the best weight-loss service for patients

Written by | 20 Jun 2023

People seeking semaglutide for weight management from a pharmacy-led service need to feel assured that the service is ethical and legal and has the best interests of the… read more.

How to provide semaglutide for ethical weight-loss

Written by | 19 Jun 2023

Taking time to understand a patient’s weight loss goals and checking their medical history to ensure there are no underlying problems that may need onward referral are both… read more.

Semaglutide: what you need to know about online supply and effective use

Written by | 18 Jun 2023

Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the… read more.

Wegovy or Ozempic – does it matter?

Written by | 17 Jun 2023

Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist… read more.

Semaglutide and how it makes you want to eat less

Written by | 16 Jun 2023

Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.